Vericel Corporation reported $306M of revenue over the trailing twelve months, +23% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $306M (to Q2 2026). Net income: $24M, trailing twelve months to Q2 2026. Free cash flow: $62M, trailing twelve months to Q2 2026. Operating margin: 4.5%, trailing twelve months to Q2 2026.

VCELVericel Corporation

Healthcare

$40.12+27% 1Y

$40.12

$29.3452 weeks$47.81

VCEL as reported

Vericel Corporation reported $306M of revenue over the trailing twelve months, +23% on the year before. 11 reported series are charted on this page, each one as filed.

$306M

Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before

Net income: $24M
Net income · +241% year on year · trailing twelve months to Q2 2026
Free cash flow: $62M
Free cash flow · −843% year on year · trailing twelve months to Q2 2026
Operating margin: 4.5%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VCEL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$306M	+23%	Q2 2026
Net income	$24M	+241%	Q2 2026
EPS	$0.47	+262%	Q2 2026
Gross margin	74%	n/a	Q2 2026
Operating margin	4.5%	n/a	Q2 2026
Net margin	6.5%	n/a	Q2 2026
ROE	5.3%	n/a	Q2 2026
ROA	3.9%	n/a	Q2 2026
ROIC	−91%	n/a	Q3 2018 · 31 quarters behind
Free cash flow	$62M	−843%	Q2 2026
P/E	85.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.